Chronic Lymphocytic Leukemia Cll clinical trials

Explore recruiting chronic lymphocytic leukemia cll clinical trials.

Recruiting chronic lymphocytic leukemia cll studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chronic Lymphocytic Leukemia Cll trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

Czechia, Italy, Poland, Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP53 Mutation

Spain, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab

Italy, Austria, Spain, Ireland, Czechia, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Clonal evolution in progressive CLL patients harboring subclonal TP53 aberrations treated with ibrutinib first-line

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)

France, Germany, Spain, Sweden, Italy, Netherlands +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Chronic Lymphocytic Leukemia Cll trials by city

Chronic Lymphocytic Leukemia Cll in Toronto Chronic Lymphocytic Leukemia Cll in Vancouver Chronic Lymphocytic Leukemia Cll in Montreal Chronic Lymphocytic Leukemia Cll in Calgary Chronic Lymphocytic Leukemia Cll in Edmonton Chronic Lymphocytic Leukemia Cll in Ottawa Chronic Lymphocytic Leukemia Cll in Winnipeg Chronic Lymphocytic Leukemia Cll in Quebec City Chronic Lymphocytic Leukemia Cll in Hamilton Chronic Lymphocytic Leukemia Cll in Kitchener Chronic Lymphocytic Leukemia Cll in London Chronic Lymphocytic Leukemia Cll in Halifax Chronic Lymphocytic Leukemia Cll in New York Chronic Lymphocytic Leukemia Cll in Los Angeles Chronic Lymphocytic Leukemia Cll in Chicago Chronic Lymphocytic Leukemia Cll in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease